Written by 12:30 pm Basal Cell Carcinoma Views: 7

Basal Cell Carcinoma

A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete

WHATNEXT partner Patient Worthy recently reported on the completion of a phase 1/2 clinical trial for basal cell carcinoma, a type of skin cancer. This trial was evaluating AiViva Biopharma’s experimental therapy AIV001, a multi-kinase inhibitor incorporating a proprietary delivery technology.

Author Jessica Lynn notes:

During the course of the study, the 26 participants were entered into four different treatment groups each focusing on a different dose. Researchers evaluated how tolerable the treatment was on skin, how safe it was, and how effective it was in clearing malignant (cancerous) cells. Researchers found that, at this point, AIV001 is well-tolerated. Moving forward, AiViva Biopharma plans to continue engaging in clinical development to advance the treatment. 

Check out the full story here.

Editor’s Note: Get Involved

Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.

(Visited 7 times, 1 visits today)

Last modified: March 25, 2024

Close